Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: Workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative (ADQI)

Contributions to Nephrology

Volumn 182, Issue , 2013, Pages 117-136

  Cruz, Dinna N ^a,j   Schmidt Ott, Kai M ^b   Vescovo, Giorgio ^c   House, Andrew A ^d   Kellum, John A ^e   Ronco, Claudio ^d   McCullough, Peter A ^f,g,h,i  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d SAN BORTOLO HOSPITAL   (Italy)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f St John Providence Health System   (United States)

^g Medical Centers   (United States)

^h St John Macomb Oakland Hospital   (United States)

ⁱ ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADRENERGIC SYSTEM; ANIMAL; ARTICLE; BLOOD; CARDIORENAL SYNDROME; CHRONIC DISEASE; CLASSIFICATION; CONSENSUS DEVELOPMENT; DISEASE MODEL; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ACUTE-PHASE PROTEINS; ANIMALS; BIOLOGICAL MARKERS; CARDIO-RENAL SYNDROME; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; LIPOCALINS; PROTO-ONCOGENE PROTEINS; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 84879093046     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000349968     Document Type: Article

References (62)

1. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J: High prevalence of renal dysfunction and its impact on outcome in 118, 465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13:422-430. (Pubitemid 47179911)
2. Hebert K, Dias A, Delgado MC, Franco E, Tamariz L, Steen D, Trahan P, Major B, Arcement LM: Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population. Eur J Heart Fail 2010; 12:861-865.
3. Cruz DN, Bagshaw SM: Heart-kidney interaction: epidemiology of cardiorenal syndromes. Int J Nephrol 2010; 2011:351291.
4. Bagshaw SM, Cruz DN, Aspromonte N, Daliento L, Ronco F, Sheinfeld G, Anker SD, Anand I, Bellomo R, Berl T, et al: Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010; 25:1406-1416.
5. Setoguchi S, Stevenson LW, Schneeweiss S: Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154:260-266. (Pubitemid 47079017)
6. Tanaka K, Ito M, Kodama M, Maruyama H, Hoyano M, Mitsuma W, Iino N, Hirono S, Okura Y, Gejyo F, et al: Longitudinal change in renal function in patients with idiopathic dilated cardiomyopathy without renal insufficiency at initial diagnosis. Circ J 2007; 71:1927-1931. (Pubitemid 350261418)
7. Chawla LS, Kimmel PL: Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 2012; 82:516-524.
8. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B: The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005; 26:11-17. (Pubitemid 40221118)
9. Merrill AJ, Morrison JL, Branno ES: Concentration of renin in renal venous blood in patients with chronic heart failure. Am J Med 1946; 1:468.
10. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM: Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 1984; 55:669-675. (Pubitemid 15176962)
11. Kishimoto T, Maekawa M, Abe Y, Yamamoto K: Intrarenal distribution of blood flow and renin release during renal venous pressure elevation. Kidney Int 1973; 4:259-266.
12. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, Suzuki F, Nagai Y, Nakano D, Hitomi H, et al: Renal sympathetic denerva-tion suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 2012; 125:1402-1413.
13. Remuzzi G, Cattaneo D, Perico N: The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008; 19: 1459-1462.
14. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T: Dual blockade of aldosterone and angiotensin II additively suppresses TGF-β and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007; 22:1314-1322. (Pubitemid 47072218)
15. Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE, Uriel N, Cotter G: Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 2012; 17:177-190.
16. Colombo PC, Onat D, Sabbah HN: Acute heart failure as 'acute endothelitis'-interac-tion of fluid overload and endothelial dysfunction. Eur J Heart Fail 2008; 10:170-175. (Pubitemid 351221388)
17. Lu J, Wang X, Wang W, Muniyappa H, Deshmukh A, Hu C, Das K, Mehta JL: Abrogation of lectin-like oxidized LDL receptor-1 attenuates acute myocardial ischemia-induced renal dysfunction by modulating systemic and local inflammation. Kidney Int 2012; 82:436-444.
18. Entin-Meer M, Ben-Shoshan J, Maysel-Auslender S, Levy R, Goryainov P, Schwartz I, Barshack I, Avivi C, Sharir R, Keren G: Accelerated renal fibrosis in cardiorenal syndrome is associated with long-term increase in urine neutrophil gelatinase-associated lipocalin levels. Am J Nephrol 2012; 36:190-200.
19. Lekawanvijit S, Kompa AR, Zhang Y, Wang BH, Kelly DJ, Krum H: Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome. Am J Physiol Heart Circ Physiol 2012; 302:H1884-H1893.
20. Angelini A, Castellani C, Ravara B, Franzin C, Pozzobon M, Tavano R, Libera LD, Papini E, Vettor R, De Coppi P, et al: Stem-cell therapy in an experimental model of pulmonary hypertension and right heart failure: role of paracrine and neurohormonal milieu in the remodeling process. J Heart Lung Transplant 2011; 30:1281-1293.
21. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, Battista Ambro-sio G, Vescovo G: Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure. Circulation 2001; 103: 2195-2200. (Pubitemid 32458329)
22. Tanaka M, Yoshida H, Furuhashi M, Togashi N, Koyama M, Yamamoto S, Yamashita T, Okazaki Y, Ishimura S, Ota H, et al: Deterioration of renal function by chronic heart failure is associated with congestion and oxidative stress in the tubulointerstitium. Intern Med 2011; 50:2877-2887.
23. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL: Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53:582-588.
24. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WHW: Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53:589-596.
25. Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL: Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9:872-878. (Pubitemid 47332311)
26. Testani JM, Kimmel SE, Dries DL, Coca SG: Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011; 4:685-691.
27. Capes SE, Gerstein HC, Negassa A, Yusuf S: Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 2000; 23:377-380. (Pubitemid 30131748)
28. Bansal N, Tighiouart H, Weiner D, Griffith J, Vlagopoulos P, Salem D, Levin A, Sarnak MJ: Anemia as a risk factor for kidney function decline in individuals with heart failure. Am J Cardiol 2007; 99:1137-1142.
29. Ljungman S, Kjekshus J, Swedberg K: Renal function in severe congestive heart failure during treatment with enalapril-the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) Trial. Am J Cardiol 1992; 70:479-487.
30. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D: Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003; 24:412-420. (Pubitemid 36286184)
31. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN: Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 2009; 120:1577-1584.
32. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, et al: Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374:543-550.
33. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717. (Pubitemid 29407370)
34. Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt B, Zannad F: Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 2012; 125:271-279.
35. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11-21.
36. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, et al: Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33:2782-2795.
37. Zannad F, Dousset B, Alla F: Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001; 38:1227-1232. (Pubitemid 34252836)
38. Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, et al: Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Circulation Heart failure 2011; 4:18-26.
39. Castagno D, Jhund PS, McMurray JJ, Lewsey JD, Erdmann E, Zannad F, Remme WJ, Lopez-Sendon JL, Lechat P, Follath F, et al: Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 2010; 12:607-616.
40. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, Babalis D, Bohm M, Coats AJ, Roughton M, Poole-Wilson P, Tavazzi L, Flather M: Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 2009; 11:872-880.
41. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133-3140. (Pubitemid 36793081)
42. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, et al: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109:1594-1602. (Pubitemid 38451714)
43. Boerrigter G, Costello-Boerrigter LC, Abraham WT, Sutton MG, Heublein DM, Kruger KM, Hill MR, McCullough PA, Burnett JC Jr: Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail 2008; 14:539-546.
44. Sandner SE, Zimpfer D, Zrunek P, Rajek A, Schima H, Dunkler D, Grimm M, Wolner E, Wieselthaler GM: Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg 2009; 87:1072-1078.
45. Awad H, el-Safty I, Abdel-Gawad M, el-Said S: Glomerular and tubular dysfunction in children with congenital cyanotic heart disease: effect of palliative surgery. Am J Med Sci 2003; 325:110-114. (Pubitemid 36348615)
46. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, et al: Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113:671-678.
47. Halbesma N, Jansen DF, Heymans MW, Stolk RP, de Jong PE, Gansevoort RT: Development and validation of a general population renal risk score. Clin J Am Soc Nephrol 2011; 6:1731-1738.
48. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS: A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011; 305:1553-1559.
49. Khan NA, Ma I, Thompson CR, Humphries K, Salem DN, Sarnak MJ, Levin A: Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol 2006; 17:244-253.
50. Cruz DN, Gaiao S, Maisel A, Ronco C, Devarajan P: Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review. Clin Chem Lab Med 2012; 50:1533-1545.
51. Cruz DN, Fard A, Clementi A, Ronco C, Maisel A: Role of biomarkers in the diagnosis and management of cardiorenal syndromes. Semin Nephrol 2012; 32:79-92.
52. Tang WH, Van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, Martin MG, Borowski AG, Jasper S, Starling RC, et al: Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail 2008; 14:394-399. (Pubitemid 351749833)
53. Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, van Veldhuisen DJ, Montagna L, Cosmi F, Tognoni G, et al: Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011; 32: 2705-2712.
54. Damman K, van der Harst P, Smilde TD, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL: Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart 2012; 98:319-324.
55. Damman K, van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL: Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010; 96:1297-1302.
56. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL: Urinary neutrophil gelatinase associated lipocalin, a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008; 10:997-1000.
57. Nymo SH, Ueland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, Wikstrand J, McMurray J, van Veldhuisen DJ, Gullestad L, et al: The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA. J Intern Med 2012; 271:436-443.
58. Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M: Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res 2009; 12:7-14.
59. Shrestha K, Borowski AG, Troughton RW, Thomas JD, Klein AL, Tang WH: Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail 2011; 17: 472-478.
60. Jungbauer CG, Birner C, Jung B, Buchner S, Lubnow M, von Bary C, Endemann D, Banas B, Mack M, Boger CA, et al: Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail 2011; 13:1104-1110.
61. Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY, Zannad F: Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 2012; 14:668-675.
62. Acute Dialysis Quality Initiative (ADQI). www.ADQI.org (accessed January 10, 2013).